Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 08/17/07 | Current report filing |
|
59 | ||
| 07/20/07 | Optional form for quarterly and transition reports of small business issuers |
|
23 | ||
| 05/14/07 | Optional form for quarterly and transition reports of small business issuers |
|
20 | ||
| 02/09/07 | Current report filing |
|
27 | ||
| 02/07/07 | Optional form for annual and transition reports of small business issuers [Section 13 or 15(d), not S-B Item 405] |
|
42 | ||
| 11/17/06 | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
2 | ||
| 11/14/06 | Optional form for quarterly and transition reports of small business issuers |
|
25 | ||
| 11/14/06 | Current report filing |
|
3 | ||
| 11/09/06 | SEC-generated letter |
|
3 | ||
| 11/08/06 | Current report filing |
|
4 |